The PATHWAY clinical trial investigated the use of tezepelumab in patients with moderate-to-severe asthma who had not been able to control their condition through long-acting beta-agonists and inhaled glucocorticoids. As part of the Phase II study, randomized participants received a low dose of the human monoclonal antibody every 4 weeks; a medium dose every 2 weeks; a high dose, also every 2 weeks; or placebo. Followup occurred after 1 year, with researchers comparing between-group differences in the annualized rate of asthma exacerbations. Compared with placebo, exacerbation rates were down 61%, 71%, and 66%, respectively, in patients taking the three different doses of tezepelumab. The effect held true even when blood eosinophil counts at enrollment were factored in, the researchers report.